Method for treating nervous system pathophysiologies using glial growth factors
AssigneesCambridge NeuroScience, Inc., Ludwig Institute for Cancer Research
InventorsAndrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for treating pathophysiological conditions of the mammalian nervous system. The methods involve administering an effective amount of a polypeptide comprising amino acids 51 to 422 of human GGF2.
Claims21
A method for the treatment of a pathophysiological condition of the nervous system in a mammal, said method comprising administering to said mammal an effective amount of a polypeptide comprising amino acids 51 to 422 of SEQ ID NO:
- 170.
A method of stimulating mitogenesis of a glial cell, said method comprising contacting said glial cell with the polypeptide comprising amino acids 51-422 of SEQ ID NO:
- 170.
A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of the polypeptide comprising amino acids 51 to 422 of SEQ ID NO:
- 170, said contacting sufficient to induce myelination of said neural cell by said glial cell.
A method for inducing acetylcholine receptor synthesis in a cell, said method comprising contacting said cell with an amount of the polypeptide comprising amino acids 51 to 422 of SEQ ID NO:
- 170, said contacting sufficient to stimulate synthesis of acetylcholine receptors in said cell.
A method for prophylaxis of a pathophysiological condition of the nervous system in a mammal, said method comprising administering to said mammal an effective amount of a polypeptide comprising amino acids 51 to 422 of SEQ ID NO:
- 170.
Dependencies are inferred from the claim text.